Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Ainos Inc. (AIMDW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/06/2025: AIMDW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -86.34% | Avg. Invested days 22 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/06/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.22 | 52 Weeks Range 0.03 - 0.31 | Updated Date 06/26/2025 |
52 Weeks Range 0.03 - 0.31 | Updated Date 06/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2978.02% |
Management Effectiveness
Return on Assets (TTM) -30.93% | Return on Equity (TTM) -82.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 9206027 |
Shares Outstanding - | Shares Floating 9206027 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Ainos Inc.
Company Overview
History and Background
Ainos Inc., formerly known as Ainos BioScience, Inc., focuses on developing and commercializing medical technologies. Founded in 2010, the company has evolved from initial research to focus on antiviral and anti-inflammatory treatments and point-of-care diagnostics. Significant milestones include the development of antiviral compounds and diagnostic platforms.
Core Business Areas
- Antiviral Therapeutics: Development of novel antiviral therapeutics targeting respiratory infections and other viral diseases. Focuses on formulations and delivery methods to enhance efficacy.
- Point-of-Care Diagnostics: Developing point-of-care diagnostic devices for rapid and accurate detection of various pathogens and biomarkers.
- Long-term Care Products: Focuses on products tailored for long term care facilities, including sanitizers and infection control solutions.
Leadership and Structure
The leadership team comprises executives with experience in pharmaceuticals, biotechnology, and medical device development. The organizational structure includes research and development, clinical operations, and commercialization divisions.
Top Products and Market Share
Key Offerings
- Veldona: Antiviral drug candidate targeting respiratory viruses. Currently in clinical development. Market share data is not yet available as the product is pre-revenue. Competitors in the antiviral space include Gilead Sciences (GILD) and Roche (ROG.SWI).
- Point-of-Care Diagnostic Platform: A rapid diagnostic platform for detecting infectious diseases. Currently in development. Market share data not available as product is pre-revenue. Competitors include Abbott (ABT) and QuidelOrtho (QDEL).
- COVID-19 Sanitizers: Offer various sanitization products tailored to the COVID-19 pandemic. No significant market share available, highly competitive market. Competitors include Proctor & Gamble (PG) and Kimberly-Clark (KMB)
Market Dynamics
Industry Overview
The pharmaceutical and diagnostics industry is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. Growing demand for innovative therapies and diagnostics drives market growth.
Positioning
Ainos Inc. positions itself as an innovator in antiviral therapeutics and point-of-care diagnostics. Competitive advantages include proprietary technology platforms and experienced management team.
Total Addressable Market (TAM)
The total addressable market for antiviral therapeutics and point-of-care diagnostics is estimated to be billions of dollars globally. Ainos Inc. is targeting specific segments within these markets, focusing on unmet needs and underserved populations. TAM estimates are between $30-$100 billion.
Upturn SWOT Analysis
Strengths
- Proprietary antiviral technology platform
- Experienced management team
- Focus on unmet medical needs
- Agile and adaptable business model
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Limited market presence
- Pre-revenue stage increases risk
Opportunities
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Increased demand for point-of-care diagnostics
- Government funding and grants
Threats
- Regulatory hurdles and delays
- Competition from established pharmaceutical companies
- Failure of clinical trials
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- GILD
- ABT
- ROG.SWI
- QDEL
Competitive Landscape
Ainos Inc. faces intense competition from established pharmaceutical and diagnostics companies. The company's success depends on its ability to differentiate its products and secure strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's focus on research and development. Growth is anticipated to accelerate upon successful commercialization of its products.
Future Projections: Future growth projections are dependent on the successful completion of clinical trials and regulatory approvals. Analyst estimates vary widely due to the uncertainty surrounding the company's pipeline.
Recent Initiatives: Recent initiatives include advancing clinical trials for Veldona, expanding the point-of-care diagnostic platform, and seeking strategic partnerships.
Summary
Ainos Inc. is a high-risk, high-reward biotechnology company focused on developing antiviral therapeutics and diagnostics. The company's strengths lie in its proprietary technology and experienced management, but its limited financial resources and dependence on clinical trial outcomes pose significant challenges. Successful commercialization of its products is crucial for the company's long-term viability, requiring vigilance about capital.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Press releases
- Analyst reports
- Industry reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data and financial projections are subject to change and may not be accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ainos Inc.
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2022-08-09 | CEO, President & Chairman of the Board Mr. Chun-Hsien Tsai | ||
Sector Healthcare | Industry Medical Devices | Full time employees 44 | Website https://www.ainos.com |
Full time employees 44 | Website https://www.ainos.com | ||
Ainos, Inc., a dual-platform AI and biotech company, focusing SmellTech, AI diagnostics, and immune therapeutics. Its AI Nose platform uses a smell language model to digitize scent into Smell IDs and turning invisible chemical signals into machine-readable data. The company is also giving AI for robotics, smart factories, senior care, and women's health. In addition, it develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases, plus applications in animal health. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.